TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan
D516NC00001
Phase 3 small_molecule active
Quick answer
TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan for Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active